annual EBITDA:
-$141.71M-$87.95M(-163.63%)Summary
- As of today (June 27, 2025), MLTX annual EBITDA is -$141.71 million, with the most recent change of -$87.95 million (-163.63%) on December 31, 2024.
- MLTX annual EBITDA is now -163.63% below its all-time high of -$53.75 million, reached on December 31, 2023.
Performance
MLTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$40.01M+$8.27M(+17.13%)Summary
- As of today (June 27, 2025), MLTX quarterly EBITDA is -$40.01 million, with the most recent change of +$8.27 million (+17.13%) on March 31, 2025.
- Over the past year, MLTX quarterly EBITDA has dropped by -$26.43 million (-194.69%).
- MLTX quarterly EBITDA is now -538.64% below its all-time high of -$6.26 million, reached on September 30, 2021.
Performance
MLTX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$161.95M-$26.43M(-19.51%)Summary
- As of today (June 27, 2025), MLTX TTM EBITDA is -$161.95 million, with the most recent change of -$26.43 million (-19.51%) on March 31, 2025.
- Over the past year, MLTX TTM EBITDA has dropped by -$107.55 million (-197.69%).
- MLTX TTM EBITDA is now -395.52% below its all-time high of -$32.68 million, reached on June 30, 2021.
Performance
MLTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MLTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -163.6% | -194.7% | -197.7% |
| 3 y3 years | - | -151.0% | -195.1% |
| 5 y5 years | - | -22.4% | -395.5% |
MLTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -163.6% | at low | -209.5% | +17.1% | -306.4% | at low |
| 5 y | 5-year | -163.6% | at low | -538.6% | +17.1% | -395.5% | at low |
| alltime | all time | -163.6% | at low | -538.6% | +17.1% | -395.5% | at low |
MLTX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$40.01M(-17.1%) | -$161.95M(+19.5%) |
| Dec 2024 | -$141.71M(+163.6%) | -$48.28M(+12.1%) | -$135.51M(+33.0%) |
| Sep 2024 | - | -$43.08M(+40.9%) | -$101.90M(+41.9%) |
| Jun 2024 | - | -$30.58M(+125.2%) | -$71.80M(+32.0%) |
| Mar 2024 | - | -$13.58M(-7.4%) | -$54.40M(+1.2%) |
| Dec 2023 | -$53.75M | -$14.67M(+13.1%) | -$53.75M(-3.4%) |
| Sep 2023 | - | -$12.97M(-1.6%) | -$55.63M(-3.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$13.18M(+2.0%) | -$57.42M(-7.2%) |
| Mar 2023 | - | -$12.93M(-21.8%) | -$61.89M(-4.6%) |
| Dec 2022 | -$64.90M | -$16.54M(+12.0%) | -$64.90M(+34.2%) |
| Sep 2022 | - | -$14.77M(-16.3%) | -$48.36M(+21.3%) |
| Jun 2022 | - | -$17.65M(+10.7%) | -$39.85M(-27.4%) |
| Mar 2022 | - | -$15.94M(+154.4%) | -$54.89M(+40.9%) |
| Sep 2021 | - | -$6.26M(-80.8%) | -$38.95M(+19.2%) |
| Jun 2021 | - | -$32.68M | -$32.68M |
FAQ
- What is MoonLake Immunotherapeutics annual EBITDA?
- What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
What is MoonLake Immunotherapeutics annual EBITDA?
The current annual EBITDA of MLTX is -$141.71M
What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual EBITDA is -$53.75M
What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
Over the past year, MLTX annual EBITDA has changed by -$87.95M (-163.63%)
What is MoonLake Immunotherapeutics quarterly EBITDA?
The current quarterly EBITDA of MLTX is -$40.01M
What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly EBITDA is -$6.26M
What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
Over the past year, MLTX quarterly EBITDA has changed by -$26.43M (-194.69%)
What is MoonLake Immunotherapeutics TTM EBITDA?
The current TTM EBITDA of MLTX is -$161.95M
What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM EBITDA is -$32.68M
What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
Over the past year, MLTX TTM EBITDA has changed by -$107.55M (-197.69%)